The aberrant dynamic amplitude of low-frequency fluctuations in melancholic major depressive disorder with insomnia

Aberrant regional neural fluctuations and functional connectivity in insomnia comorbid depression revealed by resting-state functional magnetic resonance imaging

Insomnia is a common mental illness seriously affecting people lives, that might progress to major depression. However, the neural mechanism of patients with CID comorbid MDD remain unclear. Combining fractional amplitude of low-frequency fluctuation (fALFF) and seed-based functional connectivity (FC), this study investigated abnormality in local and long-range neural activity of patients with CID comorbid MDD. Here, we acquired resting-state blood oxygenation level dependent (BOLD) data from 57 patients with CID comorbid MDD and 57 healthy controls (HC). Compared with the controls, patients with CID comorbid MDD exhibited abnormal functional activity in posterior cerebral cortex related to the visual cortex, including the middle occipital gyrus (MOG), the cuneus and the lingual gyrus, specifically, lower fALFF values in the right MOG, left cuneus, and right postcentral gyrus, increased FC between the right MOG and the left cerebellum, and decreased FC between the right MOG and the right lingual gyrus. Neuropsychological correlation analysis revealed that the decreased fALFF in the right MOG was negatively correlated with all the neuropsychological scores of insomnia and depression, reflecting common relationships with symptoms of CID and MDD. While the decreased fALFF of the left cuneus was distinctly correlated with the scores of depression related scales. The decreased FC between the right MOG and the right lingual gyrus was distinctly correlated with the scores of insomnia related scales. This study not only widened neuroimaging evidence that associated with insomnia and depressive symptoms of patients with CID comorbid MDD, but also provided new potential targets for clinical treatment.

The relationship between regional homogeneity in resting-state functional magnetic resonance imaging and cognitive function in depressive disorders with migraine

Patients with depressive disorder with migraine (DDWM) are common, yet the neural mechanisms and brain function changes associated with this comorbidity remain partially understood. This study explores regional homogeneity (ReHo) abnormalities in resting-state functional magnetic resonance imaging (fMRI) and cognitive function in DDWM patients. We recruited 29 patients with DDWM, 34 patients with depressive disorder without migraine (DDWOM), and 43 matched healthy controls (HC). All participants underwent rs-fMRI scans, and imaging data were analyzed using ReHo. Cognitive function was assessed with the Repeatable Battery for the Assessment of Neuropsychological Status. We also employed support vector machine (SVM) analysis to evaluate whether abnormal ReHo values could distinguish DDWM. he DDWM group exhibited significantly lower ReHo values in the left cuneus and left calcarine compared to the DDWOM group. ReHo values in these regions were negatively correlated with pain scores on the Visual Analogue Scale (r = - 0.3628, p = 0.0001; r = - 0.3142, p = 0.001) and positively correlated with the List_Recall score on RBANS (r = 0.260, p = 0.007). SVM analysis indicated that the left cuneus ReHo value could distinguish DDWM from DDWOM with 78.09% accuracy, 87.66% sensitivity, and 74.33% specificity. The left cuneus and left calcarine are potential biomarkers for migraine symptoms in DDWM, with the left cuneus affecting cognitive function related to memory.

Inflammation-related abnormal dynamic brain activity correlates with cognitive impairment in first-episode, drug-naïve major depressive disorder

BACKGROUND

Cognitive impairment is common in major depressive disorder (MDD) and potentially linked to inflammation-induced alterations in brain function. However, the relationship between inflammation, dynamic brain activity, and cognitive impairment in MDD remains unclear.

METHODS

Fifty-seven first-episode, drug-naïve MDD patients and sixty healthy controls underwent fMRI scanning. Dynamic amplitude of low-frequency fluctuations (dALFF) and dynamic functional connectivity (dFC) were measured using the sliding window method. Plasma IL - 6 levels and cognitive function were assessed using enzyme-linked immunosorbent assay (ELISA) and the Repeated Battery for Assessment of Neuropsychological Status (RBANS), respectively.

RESULTS

MDD patients exhibited decreased dALFF in the bilateral inferior temporal gyrus (ITG), right inferior frontal gyrus, opercular part (IFGoperc), and bilateral middle occipital gyrus (MOG). Regions of dALFF associated with IL-6 included right ITG (r = -0.400/p = 0.003), left ITG (r = -0.381/p = 0.004), right IFGoperc (r = -0.342/p = 0.011), and right MOG (r = -0.327/p = 0.016). Furthermore, IL-6-related abnormal dALFF (including right ITG: r = 0.309/p = 0.023, left ITG: r = 0.276/p = 0.044) was associated with attention impairment. These associations were absent entirely in MDD patients without suicidal ideation. Additionally, IL-6 levels were correlated with dFC of specific brain regions.

LIMITATIONS

Small sample size and cross-sectional study design.

CONCLUSIONS

Inflammation-related dALFF was associated with attention impairment in MDD patients, with variations observed among MDD subgroups. These findings contribute to the understanding of the intricate relationship between inflammation, dynamic brain activity and cognitive impairments in MDD.

Abnormal amplitude of low-frequency fluctuations associated with sleep efficiency in major depressive disorder

BACKGROUND

Sleep disturbance is one of the most frequent somatic symptoms in major depressive disorder (MDD), but the neural mechanisms behind it are not well understood. Sleep efficiency (SE) is a good indicator of early awakening and difficulty falling asleep in MDD patients. Our study aimed to investigate the relationship between sleep efficiency and brain function in MDD patients.

METHODS

We recruited 131 MDD patients from the Fourth People's Hospital in Hefei, and 71 well-matched healthy controls who were enrolled from the community. All subjects underwent resting-state functional MRI. Brain function was measured using the fractional amplitude of low-frequency fluctuation (fALFF), sleep efficiency was objectively measured by polysomnography (PSG), and clinical scales were used to evaluate depressive symptoms and sleep status. Multivariate regression analysis was performed to assess the relationship between the amplitude of the low frequency fluctuation fraction and sleep efficiency.

RESULT

Three brain regions with relevance to sleep efficiency in MDD patients were found: inferior occipital gyrus (Number of voxels = 25, peak MNI coordinate x/y/z = -42/-81/-6, Peak intensity = 4.3148), middle occipital gyrus (Number of voxels = 55, peak MNI coordinate x/y/z = -30/-78/18, Peak intensity = 5.111), and postcentral gyrus (Number of voxels = 26, peak MNI coordinate x/y/z = -27/-33/60, Peak intensity = 4.1263). But there was no significant relationship between fALFF and SE in the healthy controls.

CONCLUSION

The reduced sleep efficiency in MDD may be related to their lower neural activity in the inferior occipital gyrus, middle occipital gyrus, and postcentral gyrus. The findings may provide a potential neuroimaging basis for the clinical intervention in patients with major depressive disorder with sleep disturbances.

The Relationship between Insomnia and the Pathophysiology of Major Depressive Disorder: An Evaluation of a Broad Selection of Serum and Urine Biomarkers

Insomnia exhibits a clinically relevant relationship with major depressive disorder (MDD). Increasing evidence suggests that insomnia is associated with neurobiological alterations that resemble the pathophysiology of MDD. However, research in a clinical population is limited. The present study, therefore, aimed to investigate the relationship between insomnia and the main pathophysiological mechanisms of MDD in a clinical sample of individuals with MDD. Data were extracted from three cohorts (N = 227) and included an evaluation of depression severity (Quick Inventory of Depressive Symptomatology, QIDS-SR₁₆) and insomnia severity (QIDS-SR₁₆ insomnia items) as well as serum and urine assessments of 24 immunologic (e.g., tumour necrosis factor α receptor 2 and calprotectin), neurotrophic (e.g., brain-derived neurotrophic factor and epidermal growth factor), neuroendocrine (e.g., cortisol and aldosterone), neuropeptide (i.e., substance P), and metabolic (e.g., leptin and acetyl-L-carnitine) biomarkers. Linear regression analyses evaluating the association between insomnia severity and biomarker levels were conducted with and without controlling for depression severity (M = 17.32), antidepressant use (18.9%), gender (59.0% female; 40.5% male), age (M = 42.04), and the cohort of origin. The results demonstrated no significant associations between insomnia severity and biomarker levels. In conclusion, for the included biomarkers, current findings reveal no contribution of insomnia to the clinical pathophysiology of MDD.